Vangl2, a planar cell polarity molecule, is implicated in irreversible and reversible kidney glomerular injury

Eugenia Papakrivopoulou¹, Elisavet Vasilopoulou¹,², Maja T Lindenmeyer³,⁴, Sabrina Pacheco¹, Hortensja Ł Brzóska¹, Karen L Price¹, Maria Kolatsi-Joannou¹, Kathryn E White⁵, Deborah J Henderson⁶, Charlotte H Dean⁷, Clemens D Cohen³, Alan D Salama⁸, Adrian S Woolf⁹ and David A Long¹

¹Developmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health, London, UK
²Medway School of Pharmacy, University of Kent, Chatham Maritime, UK
³Nephrological Center, Medical Clinic and Policlinic IV, University of Munich, Munich, Germany
⁴Department of Medicine, University Medical Center Hamburg–Eppendorf, Hamburg, Germany
⁵Electron Microscopy Research Services, Newcastle University, Newcastle upon Tyne, UK
⁶Cardiovascular Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
⁷Inflammation Repair and Development Section, National Heart and Lung Institute, Imperial College London, UK.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/path.5158

This article is protected by copyright. All rights reserved.
Correspondence to: Dr Eugenia Papakrivopoulou, Developmental Biology and Cancer Programme, UCL Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK. E-mail: e.papakrivopoulou@ucl.ac.uk or Dr David A Long, Developmental Biology and Cancer Programme, UCL Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK. E-mail: d.long@ucl.ac.uk

Running title: Implicating Vangl2 in acquired kidney disease

Conflict of Interest Statement: All authors have no conflict of interests
Abstract

Planar cell polarity (PCP) pathways control the orientation and alignment of epithelial cells within tissues. Van Gogh-like 2 (Vangl2) is a key PCP protein that is required for normal differentiation of kidney glomeruli and tubules. Vangl2 has also been implicated in modifying the course of acquired glomerular disease and here we further explored how Vangl2 impacts on glomerular pathobiology in this context. Targeted genetic deletion of Vangl2 in mouse glomerular epithelial podocytes enhanced the severity of not only irreversible accelerated nephrotoxic nephritis but also lipopolysaccharide-induced reversible glomerular damage. In each proteinuric model, genetic deletion of Vangl2 in podocytes was associated with an increased ratio of active-MMP9 to inactive MMP9, an enzyme involved in tissue remodelling. Additionally, by interrogating microarray data from two cohorts of renal patients, we report increased VANGL2 transcript levels in glomeruli of individuals with focal segmental glomerulosclerosis, suggesting that the molecule may also be involved in certain human glomerular diseases. These observations support the conclusion that Vangl2 modulates glomerular injury, at least in part by acting as a brake on MMP9, a potentially harmful endogenous enzyme.

Keywords: glomerulus, kidney disease, matrix metalloproteinase, planar cell polarity, podocyte
**Introduction**

*Van Gogh-like 2* (*Vangl2*) regulates planar cell polarity (PCP), controlling orientation and alignment of epithelial cells within tissues [1]. PCP is implicated in heart [2], lung [3], neural tube [4,5] and blood vessel [6] development. In kidneys, *Vangl2* is expressed in epithelial podocytes in forming glomeruli, the blood ultrafiltration units, and in nephron and collecting duct tubules [7,8]. Homozygous *Loop-tail* mice with *Vangl2<sup>Lp</sup>* point mutations have malformed kidneys with a paucity of collecting ducts and dysmorphic glomeruli [9,10]. Although *Vangl2<sup>Lp/+</sup>* kidneys develop normally, compound heterozygotes harbouring *Vangl2<sup>Lp</sup>* and a point mutation in another PCP gene, *Cadherin EGF LAG seven-pass G-type receptor 1* (*Celsr1*), have branching malformations [11].

PCP is also implicated in acquired kidney disease. Mitotic orientation, a PCP mediated process, is aberrant in kidney cystogenesis [12]. Glomerular *Vangl2* transcripts increased 48 hours after initiation of kidney injury by nephrotoxic nephritis (NTN), a progressive disease model, and NTN is more severe in mice with podocyte-specific *Vangl2* deletion [8]. However, how *Vangl2* modulates glomerular injury is unclear. Possibly, *Vangl2* attenuates NTN-induced podocyte depletion [8]. Alternatively, *Vangl2* might modulate tissue remodelling. Indeed, *Vangl2* alters activity of matrix metalloproteinases (MMPs). *Vangl2* downregulation in zebrafish causes increased MMP14 availability, with reduced extracellular matrix (ECM) and disrupted convergent-extension [13]. *Vangl2<sup>Lp/+</sup>* mice also have both increased *Mmp12* transcripts and active protein levels in their lungs [14]. Moreover, glomerular podocytes express MMP2 and MMP9 [15,16], the latter is
upregulated in NTN [17] and experimentally downregulating MMP9 modulates NTN [17,18].

We hypothesised that Vangl2 impacts on glomerular disease by modulating MMP. We tested this by analysing mouse models of irreversible and reversible glomerular injury, both accompanied by leakage of protein into the urine. Irreversible injury was examined in NTN mice, analogous to humans with focal segmental glomerulosclerosis (FSGS). Injection of lipopolysaccharide (LPS) in mice was used to induce reversible glomerular injury, as occurs in humans with minimal change disease (MCD). Our results support the conclusion that Vangl2 modulates glomerular injury, in part by acting as a brake on MMP9.
Methods

Transgenic mice

All procedures were approved by the UK Home Office. For specific gene deletion in glomerular podocytes, we used PodCre mice which express Cre recombinase driven by the promoter of podocin, a gene expressed in podocytes from the immature capillary loop stage of glomerular development to maturity [19]. Initially, we examined the specificity of Cre recombination by breeding PodCre+ mice with R26R-EYFP mice, which have a loxP flanked STOP sequence followed by the enhanced yellow fluorescent protein gene (EYFP) inserted into the Gt(ROSA)26Sor locus. Subsequently, to delete Vangl2 in podocytes, we crossed PodCre+ mice with Vangl2flox/flox mice [20], where loxP sites flank exon 4, with PodCre+/Vangl2flox/flox mice being mated to generate PodCre+/Vangl2flox/flox mice and littermate controls, Vangl2flox/flox without Cre. Primers to detect the PodCre, Vangl2flox and excised exon 4 of Vangl2 (Δ band) alleles are detailed in Supplementary Materials and Methods. Recombination of Vangl2 by Cre generates a premature stop codon that gives rise to a protein lacking the four trans-membrane domains and the C-terminal PDZ-binding domain required for the interaction of Vangl2 with other proteins [21,22]. All transgenic mouse strains were on a C57Bl/6 background for >10 generations.

Murine models of glomerular disease

To induce accelerated NTN [23], a model of irreversible and progressive glomerular damage, male PodCre+/Vangl2flox/flox and Vangl2flox/flox mice were pre-immunised by subcutaneous injection of sheep immunoglobulin (0.2 mg) in complete Freund’s adjuvant. This was followed by intravenous administration of sheep anti-mouse glomerular
basement membrane (GBM) nephrotoxic globulin (200 μl) five days later to induce nephritis. Glomerular injury follows with capillary thrombosis and crescent formation [23].

To induce transient podocyte injury, male PodCre+/Vangl2floxflox and Vangl2floxflox mice were injected with 10 μg/g LPS intraperitoneally [24]. C57Bl/6 male wild-type mice were also injected with either phosphate buffered saline (PBS) or LPS (n=6 in each group) to examine glomerular levels of PCP genes.

**Histological analysis**

Kidneys were fixed in 4% paraformaldehyde, dehydrated, wax-embedded and sectioned at 5 μm. Periodic acid Schiff (PAS) staining was used to detect basement membranes and sclerosis. Glomerular morphology in 12-week old male PodCre+/Vangl2floxflox and Vangl2floxflox mice was examined by two blinded assessors and designated as normal (little PAS-positive material and normal capillary loops) or abnormal (PAS in >50% of the tuft). At least 30 glomeruli from four separate mice in each genotype were evaluated. Results for each category were expressed as percentage of the total glomeruli assessed. In NTN mice, thrombosis (PAS positive areas of occluded capillary loops) was scored using a scale of 0-4 depending on the number of quadrants affected within the glomerular tuft (each tuft divided into four quadrants for scoring purposes) [23]. Fifty glomeruli were assessed per sample by a blinded assessor and an average score obtained for each kidney.
Renal function assessment, immunofluorescence staining, Western blotting, electron microscopy, podocyte culture and quantitative real-time PCR (qRT-PCR)

Details are provided in the Supplementary Materials and Methods.

Studies of human kidney tissue

We interrogated microarray data obtained from microdissected glomeruli from two independent cohorts of renal patients. Cohort I was patients with FSGS (n=10), MCD (n=5) and living donor (LD) healthy controls (n=18) from the European Renal cDNA Bank [25] (Supplementary Table S1) where RNA had been hybridized to Affymetrix HG-U133 Plus 2.0 microarrays [26]. Cohort II was microarray data from the public domain (GEO database: www.ncbi.nlm.nih.gov/geo; project GSE108109; Affymetrix Human Gene 2.1 ST arrays). This project includes mRNA expression data from human renal biopsies with FSGS (n=16), MCD (n=5) and controls (LDs) (n=6). A single probe-based analysis tool, ChipInspector (Genomatix Software GmbH, Munich), was used for transcript annotation, total intensity normalisation, significance analysis of microarrays and transcript identification based on significantly changed probes [27]. The statistic algorithm in ChipInspector is a T-test which creates artificial background data by randomly permuting the array results. Each probe has a score on the basis of its fold change relative to the standard deviation of repeated measurements for this probe. Probes with scores higher than a certain threshold are deemed significant. This threshold is the Delta value. The permutations of the dataset are then used to estimate the percentage of probes identified by chance at the identical Delta. Thus, a relation of significant probes to falsely discovered probes can be given for each Delta threshold. This relation is the False Discovery Rate.
FDR, a stringency indicator. Analysis was carried out using all default settings as recommended by the software provider with a FDR of 0% and a median false positive of 0% [27].

**Statistics**

Datasets (mean±SEM) were analysed using GraphPad Prism (GraphPad software, La Jolla, CA). Differences between two groups were analysed by unpaired t-test. When comparing more than two groups, differences were analysed by one-way ANOVA with Bonferroni’s multiple comparison post-hoc tests. Data affected by two variables were analysed using two-way ANOVA with Bonferroni’s multiple comparison post-hoc tests unless otherwise stated. Statistical significance was set at \( p \leq 0.05 \).
Results

**Podocyte-specific Vangl2 knockdown mice.**

Initially, we examined the specificity of Cre recombination by breeding PodCre+ mice with R26R-EYFP mice. In the adult kidneys of PodCre+/R26R-EYFP mice (n=2) we observed positive EYFP expression in a pattern typical of podocyte expression in the glomerular tuft (Figure S1A). We subsequently bred PodCre+ mice with Vangl2flox/flox mice. PodCre+/Vangl2flox/flox and Vangl2flox/flox littermate controls both appeared healthy. DNA isolated from the kidney cortex of newborn (postnatal day 1) PodCre+/Vangl2flox/flox mice contained both the truncated Vangl2 allele and the intact allele (Figure S1B), consistent with Cre-mediated excision in podocytes that themselves represent only a proportion of Vangl2 expressing cells in the kidney cortex. We undertook qRT-PCR for Vangl2 on RNA isolated from glomeruli of 12-week old PodCre+/Vangl2flox/flox and Vangl2flox/flox mice using primers designed to span part of exon 4, finding that Vangl2 transcripts containing exon 4 were reduced to 38% in PodCre+/Vangl2flox/flox mice (p<0.05, n=4 each genotype) (Figure 1A). As assessed by Western blotting using a C-terminal antibody, Vangl2 protein was reduced to 28% in PodCre+/Vangl2flox/flox versus Vangl2flox/flox littermates (p<0.05, n=4 each genotype) in glomerular lysates from 12-week old mice (Figure 1B, C). The remaining Vangl2 expression may be due to inefficient Cre recombination. Alternatively, as the mature glomerular tuft also contains endothelia and mesangial cells, Vangl2 might also be expressed in these cells. In this regard, we found Vangl2 transcripts in cultured mouse endothelia by PCR (Figure S1C). There was no significant difference in glomerular transcripts of other core PCP components (Vangl1, Celsr1, Pk1, Pk2, Dvl1-3) or Daam1.
(encoding the downstream effector dishevelled associated activator of morphogenesis) (Figure S2).

Next, we examined glomerular morphology and function to determine whether \textit{Vangl2} is required for normal healthy glomeruli. Gross glomerular morphology was assessed in 12 week old male \textit{PodCre\textsuperscript{+}/Vangl2\textsuperscript{flox/flox}} and \textit{Vangl2\textsuperscript{flox/flox}} mice using light microscopy images of kidney sections stained with PAS (Figure 1D). Significantly (p<0.05) fewer normal (category a) glomeruli were observed in \textit{PodCre\textsuperscript{+}/Vangl2\textsuperscript{flox/flox}} mice (58.4±6.7\%) versus \textit{Vangl2\textsuperscript{flox/flox}} (84.8±3.1\%). Accordingly, the percentage of abnormal (category b) glomeruli was significantly (p<0.05) higher in \textit{PodCre\textsuperscript{+}/Vangl2\textsuperscript{flox/flox}} mice (41.6±6.7\%) compared with \textit{Vangl2\textsuperscript{flox/flox}} (15.2±2.2\%) (Figure 1E). There was no significant difference in podocyte number between the two genotypes, as assessed by quantifying the number of WT1\textsuperscript{+} cells in at least 30 glomeruli from each mouse (Figure S3). Glomerular ultrastructure was assessed by electron microscopy (Figure 1F) and no significant difference was observed in GBM or average foot process width between \textit{PodCre\textsuperscript{+}/Vangl2\textsuperscript{flox/flox}} and \textit{Vangl2\textsuperscript{flox/flox}} mice (Figure 1G-H). To assess glomerular macromolecular barrier function, we quantified albuminuria over 24 h (Figure 1I), and to examine excretion of circulating small molecules we measured plasma creatinine levels (Figure 1J). No significant differences were observed between the two genotypes for either parameter at 12 weeks.

Genetic downregulation of \textit{Vangl2} in podocytes worsens experimental nephritis. Thus, deletion of podocyte \textit{Vangl2} led to modest aberrations of glomerular morphology but this did not lead to increased albuminuria or kidney excretory failure. Therefore, we
proceeded to investigate possible roles for Vangl2 in experimentally-induced glomerular disease. We first used a model of irreversible and progressive glomerular damage, accelerated NTN. Here, mice are pre-immunised with sheep immunoglobulin, and five days later nephritis is induced by nephrotoxic globulin (Figure S4A). Previous work has shown that glomerular Vangl2 transcripts increased 48 hours after initiation of NTN [8].

Seven days after disease induction, nephropathic mice displayed a range of glomerular abnormalities including capillary thrombosis, mesangial matrix deposition, FSGS and glomerular epithelial hyperplasia, the latter representing early crescent formation (Figure 2A). We found that PodCre+/Vangl2^flox/flox mice had significantly increased glomerular thrombosis scores compared with Vangl2^flox/flox mice (2.0±0.2 versus 1.1±0.3, p<0.02 (Figure 2B). There was an approximately two-fold higher prevalence of severely damaged glomeruli (scores 2-4) in PodCre+/Vangl2^flox/flox versus Vangl2^flox/flox mice (67.7±7.1% and 36.2±14.3% respectively, (p<0.05) (Figure 2C). Following NTN, average 24 h albumin excretion was significantly increased in Vangl2^flox/flox mice versus levels before immunisation (p<0.05, Figure 2D). Strikingly, in nephropathic mice, albuminuria was an average of 2.5-fold higher in PodCre+/Vangl2^flox/flox versus Vangl2^flox/flox mice (p<0.01, Figure 2D). Plasma creatinine (Figure 2E) levels in the Vangl2^flox/flox mice seven days after NTN induction were similar to those before immunisation. In nephropathic PodCre+/Vangl2^flox/flox mice, however, creatinine significantly increased versus levels before induction of nephritis (p<0.05). As creatinine is a by-product of muscle metabolism, we also measured body weight but found no significant difference between the two nephropathic groups (Figure S4B). We measured the number of WT1^+ positive cells in at
least 30 glomeruli/mouse and found the average number of podocytes per glomerular area was not different between PodCre^{+}/Vangl2^{flox/flox} and Vangl2^{flox/flox} mice with NTN (Figure S4C, D). There was also no difference in amounts of IgG deposited within glomeruli between nephropathic PodCre^{+}/Vangl2^{flox/flox} and Vangl2^{flox/flox} mice seven days after NTN induction (Figure S4E, F), indicating that the difference in disease severity between the two groups was not due to changes in glomerular antibody binding.

We also examined whether genetic deletion of podocyte Vangl2 affected immune cell infiltration, because this modulates initiation and progression of NTN [28]. We assessed numbers of F4/80^{+} positive macrophages [29] in glomerular tufts (Figure 2F) and in areas surrounding glomeruli (Figure 2G). In glomerular tufts before injury, very few F4/80^{+} positive macrophages were detected in either genotype and there was no significant change following NTN injury. After induction of nephritis, F4/80^{+} cells around glomeruli increased in Vangl2^{flox/flox} (p<0.01) and PodCre^{+}/Vangl2^{flox/flox} kidneys, though in the latter case this did not reach statistically significance (p=0.06), but there was no difference between genotypes.

**Deletion of Vangl2 in podocytes alters MMP9 during NTN.**

We hypothesised that genetic deletion of Vangl2 in podocytes altered MMP activity, which could subsequently contribute to the increased disease severity of NTN observed in PodCre^{+}/Vangl2^{flox/flox} mice. Firstly, we knocked-down Vangl2 using siRNA in cultured mouse podocytes and measured transcript levels of Mmp2 and Mmp9, both of which have been detected in podocytes [16]. Mmp12, of which transcript levels are increased in
Vangl2 mutant lungs [14], and Mmp14, whose availability is elevated in zebrafish with Vangl2 downregulation [13]. Vangl2 siRNA resulted in a >90% knockdown in Vangl2 (Figure 3A), significantly increased mRNA levels of Mmp9 (p<0.05) (Figure 3B) but did not affect Mmp2, Mmp12 or Mmp14 (Figure 3C-E) levels (n=3 from at least 3 independent experiments analysed in triplicate). We next examined MMP9 expression in detail. MMP9 was detected on immunohistochemistry at baseline (Figure S5). Following NTN, in both Vangl2flox/flox and PodCre+/Vangl2flox/flox mice, MMP9 immunostaining partly spatially overlapped with nephrin, a podocyte slit diaphragm protein (Figure 4A-F). Using Western blots, we quantified MMP9 in whole kidneys of nephropathic Vangl2flox/flox and PodCre+/Vangl2flox/flox mice, probing with an antibody that detects both the inactive form (105 kDa; pro-MMP9) and the cleaved, enzymatically active form (95 kDa; active-MMP9) (Figure 4G). The average ratio of active MMP9 to pro-MMP9 increased by 40% in PodCre+/Vangl2flox/flox versus Vangl2flox/flox tissues (Figure 4H) (6.1±0.4 to 4.4±0.1 respectively, p<0.05, n=6-11 per group).

We examined expression of collagen IV, an MMP9 substrate [30] and a key GBM component [31], using immunofluorescent staining of kidney sections, at baseline and during NTN, with an antibody reactive to all collagen IV chains. Quantification was done by assigning a score of 0 to glomeruli with staining in <50% of the tuft area and a score of 1 to glomeruli with staining in >50% of the tuft (Figure 4I, J). There was no significant difference between Vangl2flox/flox and PodCre+/Vangl2flox/flox before induction of NTN. During NTN, collagen IV score was reduced in both Vangl2flox/flox and PodCre+/Vangl2flox/flox mice versus healthy controls (p<0.01) but no difference was observed between the two
genotypes (Figure 4M). We also quantified ZO-1, a tight junction protein [32] degraded by MMP9 in cultured podocytes [33], by immunofluorescent staining using the same scoring system (Figure 4K-L). In nephropathic mice, ZO-1 immunostaining in PodCre+/Vangl2^{flox/flox} kidneys was reduced (p<0.02) to approximately half the level measured in Vangl2^{flox/flox} organs (Figure 4N).

**Podocyte Vangl2 deletion enhances lipopolysaccharide-induced glomerular injury and modulates MMP9.**

Next, we determined whether Vangl2 plays a role in another glomerular disease model, LPS-induced reversible glomerular injury. Here, podocytes are injured through activation of the toll-like receptor 4, leading to foot process effacement within 24-48 h followed by resolution after 72 h [24]. One day after LPS administration, urinary albumin/creatinine ratio was greater (p<0.05) in PodCre+/Vangl2^{flox/flox} versus Vangl2^{flox/flox} mice by an average of 3-fold (Figure 5A). Albuminuria continued to increase in both groups until 48 h, with a non-significant (p=0.68) tendency for higher values in PodCre+/Vangl2^{flox/flox} mice (2052±1129 μg/mg) versus Vangl2^{flox/flox} animals (1465±576 μg/mg). Albuminuria returned to basal levels by 72 h in both genotypes. We examined transcript levels of Vangl1, Vangl2, Celsr1 and Pk1 in isolated glomeruli 24 h after LPS injury and found no significant differences compared with mice injected with PBS (Figure 5B). MMP9 levels in glomerular lysates from PodCre+/Vangl2^{flox/flox} and Vangl2^{flox/flox} were assessed using Western blotting (Figure 5C, D). In glomeruli harvested from either genotype before administration of LPS (n=4-6 in each group), most MMP9 was in the inactive form (Figure 5C) with ratios of active-MMP to pro-MMP9 <1 in both genotypes and no statistically significant difference.
between the genotypes (Figure 5E). LPS injury in Vangl2<sup>flox/flox</sup> mice resulted in an average ratio of active/pro-MMP9 of 1.2±0.4. Strikingly, the active/pro-MMP9 ratio in PodCre<sup>+</sup>/Vangl2<sup>flox/flox</sup> LPS glomeruli was 4.3±1.2, significantly higher (p<0.05) versus Vangl2<sup>flox/flox</sup> tissues (Figure 5F).

**Levels of PCR transcripts in human glomerular disease.**

To begin to examine the human relevance of this work, we assessed levels of transcripts encoded by PCP genes (VANGL1, VANGL2, CELSR1, CELSR2, DISHEVELED 1-3, FRIZZLED3, PRICKLE1 and PRICKLE2) in glomeruli from biopsies of individuals with either FSGS or MCD from two different cohorts of patients (Table 1). In cohort I, significant increases versus healthy controls were observed for all PCP transcripts examined in FSGS, including VANGL2 which was upregulated >1.5-fold. Similar findings were observed in cohort II with significant increases found in 6 out of the 10 genes evaluated, one of which was VANGL2. In contrast, in samples from MCD patients in cohort I, only VANGL1 and PRICKLE1 were significantly increased versus healthy kidneys, whereas CELSR1 levels were down-regulated by 0.8-fold. There were no significant changes in any of the PCP genes examined in the MCD patients in cohort II.
Discussion

Targeted genetic downregulation of Vangl2 in podocytes enhanced the severity of both accelerated NTN and LPS-induced glomerular damage. In each proteinuric model, genetic deletion of Vangl2 in podocytes was associated with an increased ratio of active-MMP9 to inactive MMP9. These observations support the conclusion that Vangl2 modulates glomerular injury in mice, at least in part by acting as a brake on MMP9, a potentially harmful endogenous enzyme. Additionally, by interrogating data from two cohorts of renal patients, we report increased VANGL2 transcript levels in glomeruli of individuals with FSGS, providing evidence that the molecule may also be involved in certain human glomerular diseases.

Previously, we [10] and others [9] showed Loop-tail (Lp) mice with homozygous point mutations in Vangl2 had malformed kidneys containing fewer ureteric tree collecting duct branches and fewer mature glomeruli. However, the Vangl2<sup>Lp/Lp</sup> mouse is not an ideal model to define the specific glomerular roles of Vangl2. First, the mutation would affect Vangl2 in both nephron and collecting duct lineages. Accordingly, because nephron, including glomerular, and collecting duct development, are interdependent, the glomerular phenotype could be a secondary effect. Secondly, homozygous Lp mutants die neonatally, precluding their use in testing roles for Vangl2 in glomerular function and disease in adulthood.

To circumvent this, we used a conditional Vangl2<sup>flx/flx</sup> mouse [19] and deleted Vangl2 specifically in glomerular podocytes. In this model, we found there were no alterations in
other PCP components in the kidney at the transcriptional level but cannot rule out possible differences in their localisation. Indeed, the \( Lp \) mutation affects the localisation of certain PCP components such as Pk2 [34], Frizzled 3 [21] and Vangl1 [35]. Based on our previous observations on the Loop-tail mouse [10] and other evidence supporting a role for Vangl2 in podocyte morphology [36], we initially hypothesised that lack of podocyte Vangl2 might result in impaired glomerular morphology and function. We found the kidneys of 12-week old \( \text{PodCre}^+/\text{Vangl2}^{\text{flox/flox}} \) did contain a slight but statistically significant increased proportion of morphologically abnormal glomeruli. This is likely explained by the fact that podocin promoter driven Cre expression, and thus Vangl2 recombination, would start in immature glomeruli, in the capillary loop stage. Kidney function, however, appeared preserved in adults as assessed by plasma creatinine and urinary albumin levels. Our results concur with Rocque and colleagues [8], who showed that podocyte-specific deletion of Vangl2 using the same \( \text{PodCre} \) line in our study led to smaller glomeruli at two weeks of age, but this also did not lead to any changes in albuminuria. Furthermore, genetic deletion of podocyte Scribble, encoding another PCP core protein, did not lead to any changes in glomerular morphology or function [37]. Collectively, these results suggest that knockdown of an individual PCP component does not have a major effect on glomerular biology of otherwise healthy mice. On the other hand, our observations on Vangl2 and Celsr1 compound heterozygous mice showed a more severe fetal glomerular defect than either mouse alone [11]. Future studies on mice lacking multiple PCP components could provide more insights into the potential role of this pathway in glomerular morphogenesis.
A key finding in our study is that glomerular injury, induced by nephrotoxic serum or LPS, is aggravated in mice with genetic downregulation of podocyte Vangl2 compared with controls. Although there was no difference in albumin excretion between PodCre\(^+\)/Vangl2\(^{flox/flox}\) and Vangl2\(^{flox/flox}\) mice before glomerular injury, we cannot rule out that the increased proportion of morphologically abnormal glomeruli seen in PodCre\(^+\)/Vangl2\(^{flox/flox}\) mice make these animals more susceptible to injury. In future, inducing NTN in mice in which Vangl2 is deleted in adulthood by an inducible PodCre allele [38] should help unravel whether the above modest glomerular maturation defect is playing a confounding role in worsening the severity of nephritis in mice with podocyte-specific Vangl2 depletion.

How might Vangl2 downregulation lead to enhanced kidney injury? Possible mechanisms include cytoskeletal rearrangements affecting cell morphology [39] or changes in inflammation [14]. However, in this study, we focused on the effect of Vangl2 downregulation on MMPs, which modulate tissue remodelling. Firstly, we examined which MMPs were altered in cultured podocytes following Vangl2 downregulation and found increased transcript levels of Mmp9. Furthermore, in both injury models, Vangl2 mutants had increased ratios of active-MMP9 to inactive MMP9. MMP9 has previously been shown to be produced by podocytes [16,33], and altered in a number of glomerular diseases including lupus nephritis with active, fibrocellular crescents [40], DN [33,41]; viral-associated glomerulonephritis [42], membranous [43] and hypertensive [44] nephropathy. MMP9 is also induced by activation of the toll-like receptor 4 [45,46] which mediates the actions of LPS. The exact mechanism of how PCP proteins regulate MMPs is not fully understood.
understood. One possibility is through the regulation of vesicular trafficking [13]. Alternatively, Vangl2 can regulate cell surface integrin αvβ3 expression and adhesion to fibronectin, laminin and vitronectin [47].

We subsequently examined some of the mechanisms through which increased MMP activity might aggravate glomerular disease in NTN. MMPs were originally characterised by their ability to break down ECM [48], therefore we examined collagen IV, a key component of the glomerular ECM [31]. However, we did not find any difference in collagen IV expression between PodCre+/Vangl2flox/flox and Vangl2flox/flox animals with NTN. Recent studies using proteomic approaches have shown that the glomerular ECM is composed of over 140 structural and regulatory components [49] and future experiments could examine the detailed ECM proteome of nephropathic PodCre+/Vangl2flox/flox and Vangl2flox/flox animals. LPS injury in mice also results in remodeling of the GBM 24 h later. A glomerular microarray study found elevated levels of transcripts encoding collagen IV α1 and α2 chains alongside laminin α5β2γ1 [50] both of which normally predominate in immature glomeruli [51]; we postulate that MMP9 may play a role in this process.

In vitro, podocyte exposure to exogenous MMP9 was shown to degrade ZO-1, a tight junction protein [32]. We also examined the distribution of ZO-1 in vivo following NTN and found a significant reduction in PodCre+/Vangl2flox/flox mice. Ultrastructure assessment of rat kidneys with NTN has shown that tight junction formation is an early abnormality in NTN, preceding foot process effacement and podocyte bridge formation [52]. The authors
postulated that podocyte-to-podocyte tight junction function may be a compensatory mechanism to maintain glomerular filtration barrier integrity. Therefore, the loss of ZO-1 in *PodCre*+/*Vangl2*^flox/flox* mice with NTN may lead to filtration barrier disruption and account for the enhanced albuminuria seen in these mice. MMP9 has also been shown to up-regulate podocyte integrin linked kinase (ILK) secretion [33], a kinase known to induce podocyte de-differentiation and detachment in disease conditions [53]; whether it is up-regulated in the setting of dysfunctional PCP remains to be elucidated. Further studies inhibiting MMPs in PCP deficient mice would help to delineate their role in this pathway. Chemical inhibition of MMP activity has already been shown to be beneficial in some models of glomerular damage [54,55] and based on our observations we would predict a similar role in dysfunctional PCP-associated glomerular damage.

To begin to examine the relevance of our mouse studies to human disease, we examined PCP transcripts in microdissected glomeruli from FSGS and MCD patients. In data from two independent cohorts of FSGS patients, significant increases *versus* living donors were observed for the majority of PCP transcripts examined. Importantly, in both FSGS cohorts *VANGL2* was upregulated >1.5-fold, suggesting this molecule may have an important biological role in FSGS. It should be noted that there were some discordant results between the two cohorts analysed (for example in the number of PCP transcripts found to be significantly altered) and follow-up studies should confirm the microarray data by qRT-PCR and assess *VANGL2* at the protein level in human glomeruli. In accord with the human data, a significant upregulation of *Dvl2, Fz3, Pk1* and *Vangl2* glomerular transcripts was detected in NTN mice 48 h after the induction of disease [8]. Interestingly, changes in
glomerular ECM deposition are a feature of FSGS and NTN [56,57] whereas in MCD or LPS glomerular disease, where there is no sclerosis or excess ECM deposition, the majority of PCP genes examined were unaltered. Collectively, the finding of \textit{VANGL2} upregulation in FSGS coupled with the observation that glomerular disease is worsened in mice deficient for \textit{Vangl2} in podocytes, suggests that increased PCP gene expression in glomerular disease is likely to be a protective compensatory response.
FIGURE LEGENDS

Figure 1. Podocyte-specific Vangl2 knockdown is associated with glomerular dysmorphology but no impairment of kidney function. (A) Vangl2 mRNA expression in glomerular isolates of Vangl2^floox/floox and PodCre^+/Vangl2^floox/floox mice by RT-qPCR (n = 4). (B) Representative western blot of glomerular lysates isolated from adult PodCre^+/Vangl2^floox/floox and Vangl2^floox/floox mice (n = 4 per genotype). (C) Semi-quantitative densitometric analysis shows that Vangl2 protein in PodCre^+/Vangl2^floox/floox mice is reduced (p<0.05) compared with littermate Vangl2^floox/floox controls. (D) Representative images of category (a)-normal and (b)-abnormal glomeruli used to assess glomerular morphology, scale bar = 20 µm. Normal glomeruli contain numerous patent capillary loops surrounded by a thin basement membrane stained red by PAS (arrows) whereas abnormal glomeruli have fewer patent capillary loops and increased PAS staining (arrows in b). (E) PodCre^+/Vangl2^floox/floox mice had fewer normal (category a) glomeruli than Vangl2^floox/floox controls and more category b glomeruli, (p< 0.05, n = 4 in each genotype, 30-50 glomeruli/sample). (F) Transmission electron micrographs of representative glomeruli from the two genotypes. Endo = endothelial cell; pod = podocyte; GBM = glomerular basement membrane; FP = foot process. Magnification= x10500. Quantification of GBM width (G) and average foot process width (H) (n = 4 in each genotype, 10 images/sample). (I) 24 h albumin excretion in urine of Vangl2^floox/floox (n = 12) and PodCre^+/Vangl2^floox/floox mice (n = 12) collected at 12 weeks. (J) Plasma creatinine concentration in Vangl2^floox/floox (n = 8) and PodCre^+/Vangl2^floox/floox mice (n = 11) at 12 weeks of age. All values are presented as mean ± SEM, ns = not significant.
Figure 2. Podocyte-specific Vangl2 knockdown exacerbates glomerular sclerosis and albuminuria following nephrotoxic nephritis. (A) Representative images of PAS-stained glomeruli used to score thrombosis, scale bar = 20 \( \mu \text{m} \). Arrows show areas of thrombosis (occluded capillary lumens) and * indicates a glomerular crescent. (B) Thrombosis score was higher and a greater percentage of glomerular were severely affected (C) (categories 2-4) in PodCre\(^+\)/Vangl2\(^{floxfloxF}\) mice compared with controls (\( n = 6-11 \) in each group, 50 glomeruli/sample). (D) 24 h albumin excretion in urine and (E) plasma creatinine concentration, \( n = 6-11 \). Quantification of F4/80+ cells in the glomerular tuft (F) and peri-glomerular area (G) of Vangl2\(^{floxfloxF}\) and PodCre\(^+\)/Vangl2\(^{floxfloxF}\) mice (\( n = 6-11 \) in each group, 30 glomeruli/sample). All values are presented as mean ± SEM, ns = not significant.

Figure 3. Vangl2 siRNA knockdown increases Mmp9 mRNA levels. Podocytes grown \textit{in vitro} under permissive conditions were differentiated for 14 days before being transfected with control siRNA or siRNA targeting Vangl2. (A) Quantification of Vangl2 RNA levels in podocytes 48 h after transfection. Relative mRNA levels of Mmp9 (B) Mmp2 (C), Mmp12 (D) and Mmp14 (E). Experiments were repeated 3 to 4 times and results are expressed as mean ± SEM. ns = not significant.

Figure 4. Podocyte-specific Vangl2 knockdown increases MMP9 activity following nephrotoxic nephritis. (A-F) Representative pictures of immunostaining for MMP9 (A and D), nephrin (B and E) and merged images (C and F) in Vangl2\(^{floxfloxF}\) and
PodCre+/Vangl2flox/flox mice (upper and lower panel respectively) following administration of nephrotoxic serum. Arrowheads indicate areas of overlapping podocyte staining in both genotypes. (G) Representative western blot for MMP9 from whole kidney lysates 7 days after NTN induction. (H) The ratio of active MMP9 to pro-MMP9 in PodCre+/Vangl2flox/flox mice is increased compared with Vangl2flox/flox controls, p<0.02, n= 6-11 in each group. (I-J) Representative images of collagen IV stained glomeruli scored 0 or 1. Arrowheads show positive staining in the glomerular tuft arising from the GBM surrounding the capillary loops. (K-L) Representative images of ZO-1 stained glomeruli scored 0 or 1. Arrowheads show positive staining in the glomerulus. (M) Quantification of Collagen IV and (N) ZO-1 staining at baseline and following NTN, expressed as average score per glomerulus, in Vangl2flox/flox and PodCre+/Vangl2flox/flox mice (n = 6-11 in each group, 30 glomeruli/sample). All values are presented as mean ± SEM, ns = not significant.

Figure 5. Podocyte-specific Vangl2 knockdown exacerbates albuminuria and increases MMP9 activity following LPS injury. (A) 8-10 week-old mice were injured with LPS (10 µg/g) and albuminuria was measured at 24, 48 and 72 h. PodCre+/Vangl2flox/flox mice had higher urine albumin to creatinine ratio at 24 h compared to Vangl2flox/flox controls (n = 5-6 per genotype), p< 0.05 by two way ANOVA and Fisher’s least square difference test. (B) qRT-PCR of core PCP genes in isolated glomeruli following injury with LPS or PBS. Representative immunoblot of MMP 9 (active and pro) in glomerular lysates from Vangl2flox/flox and PodCre+/Vangl2flox/flox mice prior to (C) and (D) 24 h following LPS. Densitometric analysis using Image J software at baseline (E) and after LPS (F) in...
PodCre+/Vangl2flox/flox mice compared to Vangl2flox/flox controls (n = 5-6 per genotype). All values are presented as mean ± SEM; ns = not significant.
ACKNOWLEDGMENTS

We thank UCL Biological Services for their assistance with animal experiments and Professor Neil Dalton (King’s College London) for creatinine measurements. This work was supported by a Wellcome Trust Postdoctoral Training Fellowship for MB/PhD graduates (095949/Z/11/Z, to EP), a PhD studentship from Kids Kidney Research (to EP and DAL), a Kidney Research UK (KRUK) Senior Non-Clinical Fellowship (SF1/2008, to DAL), a KRUK Postdoctoral Fellowship (PDF8/2015 to EV), a Medical Research Council New Investigator Award (MR/J003638/1 to DAL) and Project Grant (MR/P018629/1 to DAL and ASW) and by the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London. ASW acknowledges support from the MRC (project grant MR/L002744/1) and the Manchester Biomedical Research Centre and the Manchester Academic Health Science Centre. CDC and MTL are supported by the Else Kröner Fresenius Foundation. We thank all participating centers of the European Renal cDNA Bank and their patients for their cooperation.

Statement of author contributions

EP conceived, carried out experiments, analysed and interpreted data. EV carried out experiments and analysed data, MTL and CDC generated human mRNA data, SP, HB, KLP and MKJ carried out experiments, KEW performed electron microscopy, DJH generated and supplied the floxed Vangl2 mice, CHD was involved in study design and data interpretation, ADS generated the nephrotoxic serum, conceived experiments and was involved in data interpretation, ASW and DAL conceived experiments and interpreted
data. EP, ASW and DAL wrote the manuscript and all authors reviewed the submitted version.

SUPPLEMENTARY MATERIAL ONLINE

Supplementary Material and Methods    YES
Supplementary figures and Tables            YES

Figure S1. Characterisation of transgenic mice

Figure S2. Vangl1, Celsr1, Prickle1, Prickle2, Dvl1, Dvl2, Dvl3 and Daam1 mRNA in glomerular isolates

Figure S3. Immunostaining for WT-1 and nephrin and quantification of WT1 positive podocytes

Figure S4. The NTN model.

Figure S5. Immunostaining for MMP9 and nephrin in Vangl2\textsuperscript{flox/flox} and Pod\textsuperscript{Cre+/flox} mice at baseline.

Table S1. Disease characteristics of patients whose samples were obtained from the European Renal cDNA Bank

This article is protected by copyright. All rights reserved.
References


Table 1. Levels of PCP transcripts are altered in human glomerular disease.

<table>
<thead>
<tr>
<th>Entrez Gene ID</th>
<th>Gene Symbol</th>
<th>Cohort I FSGS (n=10) vs LDs (n=18)</th>
<th>Cohort I MCD (n=5) vs LDs (n=18)</th>
<th>Cohort II FSGS (n=16) vs LDs (n=6)</th>
<th>Cohort II MCD (n=5) vs LDs (n=6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>81839</td>
<td>VANGL1</td>
<td>1.37</td>
<td>1.24</td>
<td>1.68</td>
<td>ns</td>
</tr>
<tr>
<td>57216</td>
<td>VANGL2</td>
<td>1.53</td>
<td>ns</td>
<td>1.66</td>
<td>ns</td>
</tr>
<tr>
<td>9620</td>
<td>CELSR1</td>
<td>1.06</td>
<td>0.78</td>
<td>ns</td>
<td>ns</td>
</tr>
<tr>
<td>1952</td>
<td>CELSR2</td>
<td>1.28</td>
<td>ns</td>
<td>2.08</td>
<td>ns</td>
</tr>
<tr>
<td>1855</td>
<td>DVL1</td>
<td>1.25</td>
<td>ns</td>
<td>ns</td>
<td>ns</td>
</tr>
<tr>
<td>1856</td>
<td>DVL2</td>
<td>1.24</td>
<td>ns</td>
<td>1.70</td>
<td>ns</td>
</tr>
<tr>
<td>1857</td>
<td>DVL3</td>
<td>1.23</td>
<td>ns</td>
<td>1.69</td>
<td>ns</td>
</tr>
<tr>
<td>7976</td>
<td>FZD3</td>
<td>1.27</td>
<td>ns</td>
<td>ns</td>
<td>ns</td>
</tr>
<tr>
<td>144165</td>
<td>PRICKLE1</td>
<td>1.31</td>
<td>1.34</td>
<td>1.71</td>
<td>ns</td>
</tr>
<tr>
<td>166336</td>
<td>PRICKLE2</td>
<td>1.30</td>
<td>ns</td>
<td>0.83</td>
<td>ns</td>
</tr>
</tbody>
</table>

Single probe analysis for selected PCP transcripts in microdissected glomeruli from two independent cohorts of renal patients with focal and segmental glomerulosclerosis (FSGS), minimal change disease (MCD) and living kidney donors (LD) used as controls.
Values are expressed as fold change compared to LD. Significantly upregulated genes are shown in red and downregulated in blue. Transcripts with a fold change above 1.5 or below 0.667 are displayed in bold.
This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.